Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem is advancing the KRAS inhibitor into later stage studies following the data readout. Verastem is advancing the KRAS inhibitor into later stage studies following the data readout. Verastem will advance its KRAS inhibitor to a Phase III trial in mPDAC. Credit: UA Creative Microstocks / Shutterstock.com Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small cell lung cancer (NSCLC). In the ongoing TARGET-D 101 Phase I/II trial, VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, was investigated in patients with advanced KRAS G12D-mutated solid tumours.…

Source: Clinical Trials Arena